1 |
<p><b>PLIVA and The Althexis Company Announce a Collaboration on the Structure-Based |
2 |
Drug Design of Novel Broad Spectrum Antibiotics</b></p> |
3 |
<p>Zagreb, 8th February 1999</p> |
4 |
<p>PLIVA d.d., Zagreb, Croatia and The Althexis Company, Inc., Boston, MA., USA, |
5 |
today announced that they have entered into a collaboration to develop and commercialise |
6 |
novel broad spectrum antibiotics using structure-based drug design ("SBDD") |
7 |
technologies. PLIVA support for the Althexis program may total $14.4 million |
8 |
over three years in research funding and milestone payments. Additional future |
9 |
revenues to Althexis and PLIVA may result from certain exclusive marketing rights |
10 |
each retains under the collaboration agreement.</p> |
11 |
<p>Under terms of the agreement, PLIVA receives worldwide rights to market any |
12 |
drugs which result from two specified research projects defined in the agreement, |
13 |
except for the countries of Japan, South Korea, and Taiwan, where Althexis reserves |
14 |
those rights. The partners will each retain non-exclusive rights in China.</p> |
15 |
<p>Althexis and PLIVA will apply their expertise in the areas of structural biology, |
16 |
biophysics, biochemistry and chemistry, and in chemistry, microbiology and drug |
17 |
development, respectively, to two antibacterial targets. The companies will |
18 |
pool and share their data, including pre-clinical and clinical results, in support |
19 |
of activities in their respective geographical territories.</p> |
20 |
<p>"We are thrilled to have PLIVA as a partner in our structure-based antibiotics |
21 |
design program", stated Manuel Navia, Ph.D., a co-founder and President of The |
22 |
Althexis Company. "The last twenty years of antimicrobial research have seen |
23 |
a decline in the introduction of new antibacterials and a disturbing increase |
24 |
in the resistance to existing antibiotics. There is a pressing need to broaden |
25 |
the arsenal of antibacterial agents beyond those currently in use. Our collaboration |
26 |
agreement with PLIVA gives Althexis the financial and scientific support it |
27 |
needs to move forward against its initial bacterial targets" concluded Dr. Navia.</p> |
28 |
<p>"Our two organisations fit together very well", said Patrick Connelly, Ph.D., |
29 |
a co-founder and Chief Scientific Officer of Althexis. "Our expertise in SBDD |
30 |
nicely complements the vigorous program of drug discovery and development that |
31 |
already thrives at PLIVA. The excitement generated during our initial scientific |
32 |
discussions was palpable. Althexis has put together an impressive group of pharmaceutical |
33 |
industry veterans, as well as University and industry based joint ventures, |
34 |
to conduct its research projects. Now we can proceed expeditiously to begin |
35 |
work on the PLIVA-sponsored projects that we are so optimistic about" concluded |
36 |
Dr. Connelly.</p> |
37 |
<p>"PLIVA has a long and distinguished history of truly innovative research, dating |
38 |
back to the founding of the PLIVA Research Institute by Vladimir Prelog, 1975 |
39 |
Nobel Laureate in Chemistry. PLIVA's achievements include the discovery, development, |
40 |
and manufacture of azithromycin, the outstanding macrolide antibiotic marketed |
41 |
by Pfizer and PLIVA. We are confident that this partnership can meet the very |
42 |
ambitious development and commercialisation goals we have set and, ultimately, |
43 |
contribute to PLIVA's pipeline of novel anti-infective agents", Zeljko Covic, |
44 |
CEO of PLIVA stated.</p> |
45 |
<p>"We are extremely pleased to collaborate with The Althexis Company. PLIVA believes |
46 |
in the power of SBDD, and Althexis' expertise in this area provides us with |
47 |
a terrific complement to the antibiotics discovery program at PLIVA. This is |
48 |
a powerful collaboration and represents a unique opportunity for PLIVA to explore |
49 |
a state-of-the-art approach to making drugs" stated Radan Spaventi, M.D., Director |
50 |
of the Research Institute at PLIVA.</p> |
51 |
<p>PLIVA is the biggest pharmaceutical company in the area of Central and Eastern |
52 |
Europe and has been listed on the London Stock Exchange since 1996. In 1997, |
53 |
PLIVA acquired a majority stake in one of the biggest Polish pharmaceutical |
54 |
companies, today known as "PLIVA Krakow". PLIVA's current operations consist |
55 |
of research, the development, manufacture, and sale of pharmaceutical, animal |
56 |
health and veterinary, food, and cosmetics products. It is a company with a |
57 |
strong focus on the research and development of new chemical entities. PLIVA's |
58 |
biggest success to date has been the invention, development, and production |
59 |
of azithromycin, which was licensed to Pfizer for worldwide marketing except |
60 |
in countries where PLIVA has retained rights. Azithromycin (Zithromax, Sumamed) |
61 |
posted sales of $1 billion (US) in 1998. Several joint ventures with international |
62 |
pharmaceutical and biotechnology companies, as well as various scientific organisations, |
63 |
together with a significant reshaping of its internal research activities support |
64 |
PLIVA's commercial and strategic goals of becoming an internationally recognised |
65 |
research-driven pharmaceuticals company.</p> |
66 |
<p>The Althexis Company, based in Boston, was founded in 1998 by Drs. Manuel Navia |
67 |
and Patrick Connelly, Paul J. Mass of Mass Ventures LLC (Atlanta, GA) and Michael |
68 |
Dailey of Dailey & Partners (Southport, CT). The Althexis Company is dedicated |
69 |
to discovering novel small molecule drugs to treat diseases in humans. Althexis |
70 |
is committed to the practice of SBDD, a revolutionary approach to drug discovery |
71 |
and development that allows a smaller, more modestly capitalised company to |
72 |
compete effectively with even the largest players in the pharmaceutical industry. |
73 |
The scientific founders of Althexis have been pioneers in the establishment |
74 |
and evolution of SBDD as a scientific and commercial success.</p> |